Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026. The company also completed the sale of SomaLogic to Illumina for $350 million upfront with up to $425 million in total proceeds, leaving the company with approximately $550 million in cash and cash equivalents.

Standard BioTools will report its second quarter 2025 financial results on August 11, 2025, hosting a conference call at 4:30 p.m. ET to discuss financial performance and operational progress.

Standard BioTools Inc. (NASDAQ: LAB) announced that it will report its first quarter 2025 financial results on May 6, 2025, and host a conference call to discuss the results and operational progress.

Standard BioTools Inc. (NASDAQ: LAB) announced preliminary and unaudited revenue results for the fourth quarter and full year 2024, with expected revenue of approximately $46.5 million for Q4 2024 and $174 million for the full year 2024. The company's CEO discussed progress in reducing operating expenses and plans to leverage the company's foundation to scale and shift revenues towards high-margin offerings.

Standard BioTools Inc. (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 16th, 2024.

Standard BioTools Inc. announced the appointment of Alex Kim as its new Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and former Chief Operating Officer, brings extensive financial and operational experience in the healthcare and life sciences industries.

Standard BioTools Inc. (Nasdaq: LAB) will report its third quarter 2024 financial results on October 30, 2024 and host a conference call and webcast to discuss the results.

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V:LAB | OTCQX:NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that, further to its press releases dated April 22, 2024 and May 23, 2024, Shareholders voting at the Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 27, 2024 approved the sale of the Kingsway Project to New Found Gold Corp. (“NFG”) by a majority of 87.8%.

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer® Reagents and deliver precise information about protein binding and biomarker characterization to customers.

TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V:LAB | OTCQX:NKOSF | FNR:2N6) (“LabGold” or the “Company”) is pleased to announce that further to its press release dated April 22, 2024, the Company is providing an update on the sale of the Kingsway Project as required by the policies of the TSX Venture Exchange (“TSXV”). Pursuant to the Definitive Agreement with New Found Gold Corp. (“NFG”), NFG will acquire a 100% interest in the Kingsway Project, including all property and mining rights associated with the property, (the “Transaction”) in exchange for $20,000,000 CAD (the “Purchase Price”) payable and satisfied by the delivery to LabGold of such number of NFG Common Shares (the “Consideration Shares”) determined by dividing the Purchase Price by the closing price of the NFG Common Shares on the last trading day prior to the closing of the Transaction. The Consideration Shares will be subject to a resale restriction of four months and one day from the closing of the Transaction.

Standard BioTools to Participate in Upcoming Investor Conferences